Karen Potts
Keine laufenden Positionen mehr
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Joseph Klein | M | 62 | 19 Jahre | |
Suneet Varma | M | 55 | 23 Jahre | |
Matt Buck | M | - | 19 Jahre | |
Mike McDermott | M | 58 | 21 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Jeffrey Kindler | M | 68 | 8 Jahre | |
George A. Lorch | M | 82 | 15 Jahre | |
Jeffrey Stein | M | 69 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 6 Jahre |
John Schmid | M | 61 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 9 Jahre |
Vivid Sehgal | M | 56 | 8 Jahre | |
Everett Cunningham | M | 57 | 9 Jahre | |
John Thompson | M | 57 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 7 Jahre |
Michael Morneau | M | 58 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 5 Jahre |
Sharon Real | M | 60 |
Agouron Pharmaceuticals LLC
Agouron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Agouron Pharmaceuticals LLC develops and distributes therapeutic products. It provides therapeutic products which are used in the treatment of cardiovascular disease, central nervous system diseases and disorders, neurological disorders, inflammatory diseases, respiratory diseases, infectious diseases, immunological disorders, pharmaceutical preparations and other diseases. The company was founded in 1984 and is headquartered in San Diego, CA. | 12 Jahre |
George Milne | M | 80 | 32 Jahre | |
Olivier Brandicourt | M | 68 | 13 Jahre | |
Theodore Schroeder | M | 69 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 4 Jahre |
Risa Stack | M | 55 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 5 Jahre |
Brendan M. O'Leary | M | 52 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 3 Jahre |
Donald D. Tartre | M | 64 |
Agouron Pharmaceuticals LLC
Agouron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Agouron Pharmaceuticals LLC develops and distributes therapeutic products. It provides therapeutic products which are used in the treatment of cardiovascular disease, central nervous system diseases and disorders, neurological disorders, inflammatory diseases, respiratory diseases, infectious diseases, immunological disorders, pharmaceutical preparations and other diseases. The company was founded in 1984 and is headquartered in San Diego, CA. | 4 Jahre |
Dawn Hudson | F | 66 | 6 Jahre | |
Michael Powell | M | 69 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 5 Jahre |
Alexandra Kropotova | M | 51 | 5 Jahre | |
Philip Needleman | M | - |
G.D. Searle LLC
| 4 Jahre |
Paul Fitzhenry | M | 64 | 4 Jahre | |
Deborah Dunsire | M | 61 | 9 Jahre | |
William Herbert Gray | M | 82 | 13 Jahre | |
Matthew Onaitis | M | 53 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | - |
Robert N. Burt | M | 86 | 11 Jahre | |
Michael R. Jirousek | M | 65 | 5 Jahre | |
Peter Corr | M | 76 | 6 Jahre | |
Rajmund Ireneusz Martyniuk | M | 62 | 4 Jahre | |
Carol Szeto | F | - | 6 Jahre | |
Rajiv Sarman Shukla | M | 49 | 5 Jahre | |
David J. Wustrow | M | 65 | 2 Jahre | |
Arthur Lee Campbell | M | 73 | - | |
Michael Bruce | M | - | 12 Jahre | |
Charles Baum | M | 65 | 9 Jahre | |
Catherine Knupp | M | 63 | - | |
Dario Paggiarino | M | 67 | 10 Jahre | |
James Christensen | M | 55 | 10 Jahre | |
Anna Levander | F | 47 | 3 Jahre | |
Gail Cawkwell | M | 62 | 14 Jahre | |
Julie Krop | M | 57 | 2 Jahre | |
Mary Winston | F | 62 | 7 Jahre | |
Mariano García-Valiño | M | 58 | 8 Jahre | |
John F. Niblack | M | 85 | 35 Jahre | |
William Pringle | M | 56 | 6 Jahre | |
Deborah Baron | F | 55 | - | |
Michelle Nasir | F | - | 6 Jahre | |
Tod Smeal | M | 59 | 12 Jahre | |
Tanya de Foras | F | 53 | 10 Jahre | |
Adrian Otte | M | - | 6 Jahre | |
Muriel Cottard | M | - | 4 Jahre | |
Mark J. Taisey | M | - | 5 Jahre | |
Edmund Harrigan | M | 71 | 12 Jahre | |
Mark White | M | 68 | 12 Jahre | |
Michael Warner | M | - | 16 Jahre | |
Bruce Curtis Crosby | M | - | 2 Jahre | |
Jeffrey Kent | M | 62 | 4 Jahre | |
Matthew Rossen | M | 47 | 9 Jahre | |
John Chapman | M | 70 | 4 Jahre | |
Feng Guo | M | 54 | 11 Jahre | |
Viviane Monges | F | 60 | 5 Jahre | |
Ebrahim Versi | M | 71 | 4 Jahre | |
Krishan K. Arora | M | 83 | 5 Jahre | |
William J. Creelman | M | 69 | 1 Jahre | |
William J. Robison | M | 88 | 40 Jahre | |
Philip D. Worboys | M | 54 | 2 Jahre | |
Brian Goldberg | M | 50 | 2 Jahre | |
Linda Armstrong | M | 61 | 6 Jahre | |
William Sigmund | M | - | 4 Jahre | |
Kenneth Bahrt | M | 71 | 4 Jahre | |
Marc Robinson | M | 63 | 6 Jahre | |
Warren R. Winter | M | - | 15 Jahre | |
Claus Egstrand | M | 63 | 3 Jahre | |
Scott Kay | M | - | 7 Jahre | |
Pat Parr | M | - | 6 Jahre | |
Robert Zerbe | M | 73 | 7 Jahre | |
Michael Berendt | M | 75 | 18 Jahre | |
Wendell Wierenga | M | 76 | 10 Jahre | |
Christopher S. Hassan | M | 63 | 4 Jahre | |
Steven Ward | M | 64 | 15 Jahre | |
Alexander Polinsky | M | 67 | 8 Jahre | |
Beth Anne Piper | M | - | 3 Jahre | |
William R. Howell | M | 88 | 9 Jahre | |
Thomas G. Gant | M | - | 6 Jahre | |
Nicholas Lee Gurreri | M | - | 4 Jahre | |
Lauren Silverman | M | 69 | 5 Jahre | |
Annika Berg | F | 61 | 2 Jahre | |
Charles McWherter | M | 69 | 4 Jahre | |
Malvina Laudicina | F | 65 | 5 Jahre | |
Frank Sciavolino | M | 83 | 35 Jahre | |
Marylou Walker | F | 58 | 10 Jahre | |
William J. Slichenmyer | M | 66 | 7 Jahre | |
Yvonne R. Jackson | F | 74 | 3 Jahre | |
Julie A. Olson | M | - | 19 Jahre | |
James L. Freddo | M | 69 | 3 Jahre | |
Navin Jacob | M | - | 3 Jahre | |
Allen Waxman | M | 61 | 5 Jahre | |
Jing Wei Zhang | M | 56 | 20 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 100 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Karen Potts
- Persönliches Netzwerk